Syndax Pharmaceuticals Inc — Form 8-K

Syndax Pharmaceuticals achieved Q2 2026 total revenue of $72.8M ($54.7M Revuforj product revenue +91% YoY; $18.1M Niktimvo collaboration revenue from Incyte's $60.3M net revenue, of which Syndax records 50% of profit). The company reported ~1,500 total prescriptions for Revuforj (+121% YoY) and ~5,750 Niktimvo infusions in Q2. Cash position stands at $575.1M as of June 30, 2026, with 89.4M shares outstanding. Company expects $400M in combined R&D and SG&A expenses for full-year 2026 and projects reaching profitability. Two new pipeline assets announced: SNDX-4321 (allosteric EGFR inhibitor for NSCLC) and SNDX-62122 (next-generation menin inhibitor for myelofibrosis), both with IND submissions and Phase 1 initiations expected in 2027.